Oz Adler

SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase IIb clinical trial for its medication to treat Tourette Syndrome (TS). This...

SciSparc Ltd. (NASDAQ:SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. What Happened The Israeli specialty clinical-stage...

SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder. SCI-210 is a combination of CBD and...

The ongoing collaboration between SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE: CWY) resulted in the Tuesday filing of three patent applications under the International Patent Cooperation Treaty. SciSparc, a specialty clinical-stage pharmaceutical company...

SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the European Patent Office has granted it a new patent. The European Application No. 16786064.2 - titled Combinations of Cannabinoids and N-Acylethanolamines - aligns with the company's objective to increase the safety of cannabinoid...

SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed an agreement with the Soroka University Medical Center, located in Be'er-Sheva, Israel. What's It About? SciSparc,...

SciSparc Ltd. (NASDAQ: SPRC) has entered into a non-binding letter of intent for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution, to Jeffs' Brands Ltd. (NASDAQ: JFBR), a data-driven e-commerce company operating on Amazon (NASDAQ:...

SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with Clearmind. The patent application is the third of the...

SciSparc Ltd. (NASDAQ: SPRC) signed a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution, an Amazon.com (NASDAQ: AMZN) Marketplace account, American food supplements and cosmetics brand and trademark. The company...

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational,...

SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction. The patent application refers to the proprietary combination of SciSparc's CannAmide with...